IQVIA Holdings Inc. (IQV)
160.10 +0.79 (0.50%)
After hours: 4:26PM EDT
| Previous Close | 159.64 |
| Open | 160.41 |
| Bid | 159.13 x 1100 |
| Ask | 160.14 x 900 |
| Day's Range | 158.96 - 161.96 |
| 52 Week Range | 81.79 - 169.14 |
| Volume | 712,888 |
| Avg. Volume | 1,198,523 |
| Market Cap | 30.471B |
| Beta (5Y Monthly) | 1.33 |
| PE Ratio (TTM) | 238.13 |
| EPS (TTM) | 0.67 |
| Earnings Date | Oct. 28, 2020 - Nov. 02, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 184.17 |
- Business Wire
IQVIA’s Nancy Dreyer and Deepa Desai Honored with 2020 PharmaVOICE Awards
IQVIA™ (NYSE: IQV) today announced that Nancy Dreyer, chief scientific officer and senior vice president, Real World Solutions, has been awarded PharmaVOICE magazine’s Red Jacket honor after she was recognized multiple times as a PharmaVOICE 100. IQVIA’s Deepa Desai, vice president and head, Quality Management Systems, Quality Assurance, was honored on the 2020 PharmaVOICE 100 List, which identifies the most influential and inspiring leaders within the life sciences industry.
- Business Wire
Drug Prices Have Become More Affordable to Most Patients, says U.S. Medicine Spending Study from the IQVIA Institute for Human Data Science
The vast majority of patients in the United States are experiencing lower out-of-pocket costs for their drugs, paying a smaller share of costs and seeing a downward trend in their costs on average. That’s according to the latest report from The IQVIA™ Institute for Human Data Science, Medicine Spending and Affordability in the U.S.: Understanding Patient Costs for Medicines. The improved affordability for patients is due to changes in health insurance benefit design, a higher use of generics, record low price increases on branded drugs and more patients reaching "catastrophic" coverage levels.
- Zacks
IQV vs. SSTI: Which Stock Should Value Investors Buy Now?
IQV vs. SSTI: Which Stock Is the Better Value Option?
